- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Bosulif
Synonyms :
bosutinib
Class :
Antineoplastics and Tyrosine Kinase Inhibitor
Brand Name :
Bosulif
Synonyms :
bosutinib
Class :
Antineoplastics and Tyrosine Kinase Inhibitor
chronic Myelogenous leukemia (CML)
400
mg
Orally
once a day
Tablet
Continue the therapy until disease progression or patient intolerance occurs
chronic Myelogenous leukemia (CML)
Safety and efficacy not established
chronic Myelogenous leukemia (CML)
Refer adult dosing
when both drugs are combined, there may be a decrease in the serum concentration of bosutinib
it may decrease the serum concentration of bosutinib
it may decrease the serum concentration of bosutinib
it may decrease the serum concentration of bosutinib
it may decrease the serum concentration of bosutinib
it may decrease the serum concentration of bosutinib
it may decrease the serum concentration of bosutinib
it may decrease the serum concentration of bosutinib
when both drugs are combined, there may be an increased level of bosutinib by p-glycoprotein (mdr1) efflux transporter
when both drugs are combined, there may be a diminishing of the therapeutic effect of bcg (intravesical)
when both drugs are combined, there may be an increase in the myelosuppressive effect
it may decrease the serum concentration of bosutinib
it may increase the serum concentration of bosutinib
It may diminish the effect when combined with phenobarbital by affecting the intestinal/hepatic enzyme CYP3A4
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
nafcillin will decrease the effect of action of bosutinib by affecting enzyme CYP3A4 metabolism.
the effect of bosutinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increased effect of bosutinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
lapatinib increases the effect of bosutinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bosutinib
CYP3A4 inducers decrease the concentration of bosutinib in serum
CYP3A4 inhibitors increase the concentration of bosutinib in serum
metronidazole enhances the effect of bosutinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increased risk of adverse effects
may enhance the serum concentration of CYP3A4 inhibitors
aminosalicylic acid derivatives
it may increase the myelosuppressive effect
when both drugs are combined, there may be an increase in the serum concentration of cyp3a4 substrates
qt-prolonging agents: it may increase the qtc-prolonging effect of haloperidol
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
QTc interval is increased both by lenvatinib and bosutinib
increases the serum concentration of cabazitaxel by MDR1 efflux transporter
May increase serum level and toxic effects of docetaxel by affecting MDR1/PG-P efflux transporter
when both drugs are combined, there may be an increased QTC interval
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
relugolix/estradiol/norethindrone
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the risk or severity of toxic effects when combined
may decrease the serum concentration of CYP3A4 Inducers
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
Adverse drug reactions:
Frequency defined
>10%
Newly diagnosed CP CML
All grades
Creatinine increased (94%)
Hemoglobin decreased (89%)
Lymphocyte count decreased (84%)
Lipase increased (53%)
WBC decreased (50%)
Hepatic dysfunction (45%)
ANC decreased (42%)
Alkaline phosphatase increased (41%)
Diarrhea (75%)
Platelet count decreased (68%)
Serum glutamic-pyruvic transaminase (SGPT)/ALT increased (68%)
Glucose increased (57%)
Calcium decreased (55%)
Phosphorus decreased (54%)
Rash (40%)
Abdominal pain (39%)
Nausea (37%)
Creatine kinase increased (36%)
Fatigue (33%)
Amylase increased (32%)
Dyspnea (11%)
Decreased appetite (11%)
Respiratory tract infection (27%)
Headache (22%)
Vomiting (21%)
Arthralgia (18%)
Pyrexia (17%)
Edema (15%)
Constipation (13%)
Back pain (12%)
Pruritus (11%)
Cough (11%)
Grade 3 or 4
Lipase increased (19%)
Platelet count (14%)
SGOT/AST increased (13%)
Lymphocyte count (12%)
SGPT/ALT increased (26%)
Hepatic dysfunction (27%)
Pruritus (11%)
Hypertension (11%)
Imatinib-resistant or -intolerant Ph+ CP, AP, and BP CML
All grades
SGPT/ALT increased (39-58%)
WBC decreased (51-57%)
Calcium decreased (45-55%)
SGOT/AST increased (37-50%)
Abdominal pain (36-49%)
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: bosutinib (Rx)
Pronounced: boe-SUE-tin-ib
Why do we use bosutinib?
bosutinib is an anticancer drug belonging to the sub-class of Tyrosine Kinase inhibitors used to treat a blood cancer known as chronic myeloid leukemia. It helps in inhibiting the growth and spread of cancer cells.